Ausbil Investment Management Ltd Purchases Shares of 7,315 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Ausbil Investment Management Ltd acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 2nd quarter, Holdings Channel reports. The fund acquired 7,315 shares of the medical instruments supplier’s stock, valued at approximately $492,000.

Other hedge funds have also modified their holdings of the company. Harbor Capital Advisors Inc. acquired a new position in LeMaitre Vascular during the 2nd quarter worth approximately $26,000. Captrust Financial Advisors increased its stake in LeMaitre Vascular by 555.3% in the 1st quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 522 shares during the last quarter. FMR LLC grew its holdings in shares of LeMaitre Vascular by 111.7% in the 1st quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 334 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in LeMaitre Vascular by 143.3% during the first quarter. Benjamin Edwards Inc. now owns 1,068 shares of the medical instruments supplier’s stock worth $55,000 after acquiring an additional 629 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in LeMaitre Vascular by 241.1% during the first quarter. Tower Research Capital LLC TRC now owns 1,354 shares of the medical instruments supplier’s stock valued at $70,000 after purchasing an additional 957 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Trading Down 0.1 %

NASDAQ LMAT traded down $0.06 during trading on Monday, reaching $57.02. The company’s stock had a trading volume of 15,306 shares, compared to its average volume of 101,256. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 50.17, a price-to-earnings-growth ratio of 5.46 and a beta of 0.97. LeMaitre Vascular, Inc. has a 12 month low of $41.78 and a 12 month high of $68.67. The firm has a 50 day moving average price of $59.47 and a 200 day moving average price of $58.91.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.05. The business had revenue of $50.12 million for the quarter, compared to analysts’ expectations of $48.29 million. LeMaitre Vascular had a net margin of 14.23% and a return on equity of 9.33%. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.3 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 31st. Shareholders of record on Thursday, August 17th were given a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend was Wednesday, August 16th. LeMaitre Vascular’s dividend payout ratio is presently 49.56%.

Analysts Set New Price Targets

LMAT has been the subject of several recent analyst reports. Barrington Research increased their price objective on LeMaitre Vascular from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Wednesday, August 2nd. Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, August 2nd. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday. Oppenheimer initiated coverage on LeMaitre Vascular in a research note on Tuesday, September 5th. They issued an “outperform” rating and a $70.00 price objective on the stock. Finally, Jefferies Financial Group downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating and lifted their target price for the stock from $63.00 to $67.00 in a research note on Thursday, August 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $69.50.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.